TORONTO, Oct. 19, 2021 (GLOBE NEWSWIRE) – Field Trip Health Ltd. (FTRP, TSX: FTRP) (“Field Trip”), a world leader in the development and delivery of psychedelic therapies, today announced the opening of its Seattle Clinic, their sixth in the United States, as well as the recent opening of a location in Fredericton, New Brunswick, and the imminent opening of a location in Vancouver, British Columbia. As the world’s largest provider of psychedelic therapies, Field Trip continues to distinguish itself as a leader in the emerging psychedelic industry with continued expansion and growing demand.
Mental health continues to be a national health crisis as rates of anxiety, depression and PTSD continue to rise. Since opening its first location in March 2020, Field Trip’s Ketamine Assisted Therapy (KAP) protocols have generated rapid and significant improvements for many Field Trip customers, as measured by the Depression Scales and anxiety. Based on the data collected to date, Field Trip customers have reported that their symptoms of depression have improved significantly from ‘severe’ to ‘mild’ on average (the average PHQ9 score of respondents dropping from 17 to 6). ), and among respondents, these benefits were maintained for 120 days or more from the start of treatment. These results suggest that the benefits of Field Trip’s KAP program may compare favorably to ketamine infusions. Each Field Trip Health Center is designed to provide an oasis-like setting with elements of nature to give Field Trip clients a space for healing, growth and transformation through psychedelic therapies. The entire experience is supported by digital technology and Field Trip tools that guide people through the process, from approval of treatment to the end of their treatment program, and -of the.
Dr Ryan Yermus, Clinical Director of Field Trip Health, said: “Since opening our first clinic in Toronto, we have demonstrated the transformative power of our psychedelic therapy protocols for people struggling with their mental health. As we continue to expand into new markets, the potential to positively change people’s lives is endless. We are extremely excited to bring top notch psychedelic therapies to the communities of Seattle, Vancouver and Fredericton. “
Hannan Fleiman, President of Field Trip, added: “Each center opening lays the foundation for the development of new psychedelic therapies. Not only do we heal the community with the provision of psychedelic medicine to patients, but we also take care of the evolution of the psychedelic awakening that is occurring in the field of mental health.
The Seattle clinic’s address is 1200 Westlake Ave N Suite 600, Seattle, WA 98109 and those interested in KAP in Seattle can contact us by phone (1-888-519-6016) or email ([email protected]). The address of the Fredericton clinic is 2398 Lincoln Rd Suite 3, Lincoln, NB E3B 7E6 and those interested in KAP in Fredericton can get in touch by phone (1-833-222-0084) or email ([email protected]).
About Field Trip Health Ltd.
Field Trip is the world leader in the development and supply of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules and leading advanced research on plant-based psychedelics, including psilocybin-producing fungi and our Field Trip Health division building centers for psychedelic therapy. Opening up across North America and Europe with the digital and technological tools that will enable massive scale, we help people in treatment to those seeking accelerated personal growth, with a simple, evidence-based way to heal and scale up engagement with the world.
Learn more about https://www.meetfieldtrip.com, https://www.fieldtriphealth.com and https://www.fieldtriphealth.nl.
Follow us on Twitter and Instagram: @fieldtriphealth
To receive company updates on Field Trip and be added to the email distribution list, please subscribe here.
For more information, contact Ronan Levy, Executive Chairman and Director of Field Trip, at 1 (833) 833-1967.
Caution regarding forward-looking information.
This press release contains forward-looking information (within the meaning of Canadian securities laws and the US Private Securities Litigation Reform Act of 1995) regarding Field Trip and its activities. Often, but not always, forward-looking information can be identified by the use of words such as “expect”, “intend”, “anticipate”, “believe” or variations (including negative variations). ) of those words and expressions, or state that certain actions, events or results “may”, “could”, “would” or “will” be undertaken, occur or be achieved. These statements are based on the current expectations and views of future events of the management of Field Trip, and are based on assumptions and subject to risks and uncertainties. Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this press release may not occur and could differ materially due to known and unknown risk factors and uncertainties affecting companies, including patient adoption of therapy-assisted psychotherapy. ketamine in existing and new clinics, interest in the ketamine-assisted psychotherapy training program, interest in the KAP Co-Op program, adoption of the KAP Co-Op program by therapists and patients, timing and outcomes of its research and development programs, the approval of phase 1 human trials, if applicable, the risk that future clinical studies may not go as planned or may produce unfavorable results, the opening of additional clinics, ‘COVID-19 epidemic, the medical clinic industry, market conditions, economics, management’s ability to manage th t to operate the business and the stock market in general. Although Field Trip has attempted to identify material factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or or results differ from those anticipated, estimated or intended. Therefore, readers should not place undue reliance on forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Field Trip assumes no obligation to publicly update or revise any forward-looking statement, whether whether as a result of new information, future events, or otherwise.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities.
Neither the Toronto Stock Exchange nor its regulatory services provider has endorsed the contents of this release or accepts responsibility for the adequacy or accuracy of this release.
Nick Opich / McKenna Miller
KCSA strategic communication
212-896-1206 / 347-487-619
KCSA strategic communication
SOURCE Field Trip Health Ltd.